Spain : Zeltia gets EU approval for ovarian cancer drug.
Byline: pinto03
Spanish pharmaceutical group Zeltia /quotes/comstock/06x!czel
(ES:ZEL ZEL Zero-Length Launch 4.37, +0.34, +8.44%) on Monday said the European Union European Union (EU), name given since the ratification (Nov., 1993) of the Treaty of European Union, or Maastricht Treaty, to the
European Community has
approved the sale of its Yondelis drug to treat recurring ovarian
cancer ovarian cancer
Malignant tumour of the ovaries. Risk factors include early age of first menstruation (before age 12), late onset of menopause (after age 52), absence of pregnancy, presence of specific genetic mutations, use of fertility drugs, and personal history of breast .
Copyright : Euclid Infotech Pvt. Ltd.
Provided by Syndigate.info an Albawaba.com company
COPYRIGHT 2009 Al Bawaba (Middle East) Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion